Proposal to list medical devices supplied by Pro-Med Technologies Limited
Pharmac is seeking feedback on a proposal to list a range of medical devices in Part III of Section H of the Pharmaceutical Schedule.
What we’re proposing
Pharmac is seeking feedback on a proposal to list medical devices supplied by Pro-Med Technologies Limited (“Pro-Med”) in Part III of Section H of the Pharmaceutical Schedule from 1 April 2022 through a non-exclusive provisional agreement.
We propose to list medical devices supplied by Pro-Med in the following categories:
- Anaesthetic machines, invasive ventilators, neonatal care and critical care patient monitoring (“critical care”); and
- Patient assessment, monitoring and treatment ("patient monitoring").
Consultation closes at 4pm Monday 28 February 2022 and feedback can be emailed to email@example.com.
What would the effect be?
From 1 April 2022 medical devices in the categories listed above would be listed under a proposed national agreement (“Agreement”) that all DHB hospitals may purchase under, subject to consultation and approval by Pharmac’s Board or delegate.
The Agreement would not be for sole supply and DHBs can continue to purchase other suppliers’ brands of Critical Care products and Patient Assessment, Monitoring and Treatment medical devices.
The Agreement would supersede any existing DHB contracts with Pro-Med for the medical devices included in the Agreement. Any medical device listed in the Agreement, and purchased by a DHB, would be in accordance with the terms and conditions, including price, stated in the Agreement effective from the date of listing in the Pharmaceutical Schedule.
Pricing for the medical devices in the Agreement, subject to any prior termination of the Agreement, would not be increased without prior consultation and approval by Pharmac.
Who we think will be interested
- DHB clinical staff in a range of different clinical settings including but not limited to:
- Patient Monitoring
- Wards and Outpatient Clinics
- Perioperative staff
- Clinical engineers and maintenance services
- DHB procurement and supply chain
- Suppliers and wholesalers
About the medical devices
Critical care is the provision of specialised, continuous, multidisciplinary care for patients in a life-threatening, but treatable, condition. The critical care devices can loosely be grouped into three categories:
- Anaesthetic and invasive ventilation devices
- Neonatal care devices
- Critical care patient monitoring
Patient assessment, monitoring and treatment
Patient assessment, monitoring and treatment devices include equipment and consumable medical devices that are used in a variety of clinical settings to assess, monitor and treat patients.
Clinical areas of use include Audiology, Ear, Nose and Throat (ENT), Dermatology, Gastroenterology, Neurosciences and Psychology, Ophthalmology, Somnology, Urology, Vascular Medicine, Wards and Outpatient Clinics.
Why we’re proposing this
Pharmac has previously released the following Requests for Proposals (RFPs):
- supply of anaesthetic machines, invasive ventilation devices and critical care patient monitoring devices
- supply of multi-category patient assessment, monitoring and treatment equipment and consumables
The RFPs were for non-exclusive national agreements for listing on the Pharmaceutical Schedule.
Pharmac has been working with suppliers who responded to the RFP to seek provisional agreements. This proposal is the latest to arise from these processes and we expect to consult on further provisional agreements with suppliers in these categories throughout 2022.
Details about our proposal
Pharmac has entered into a provisional agreement with Pro-Med for the supply of critical care and patient assessment, monitoring and treatment devices.
The proposal would result in the listing of medical devices in the following brands and quantities:
Number of devices
Patient assessment, monitoring and treatment devices
Further information, including pricing and contractual details, has been provided to DHB Procurement personnel. Clinicians interested in further detail on what this change means for their DHB should engage with their Procurement teams.
To provide feedback
Send us an email: firstname.lastname@example.org by 4pm 28 February 2022.
All feedback received before the closing date will be considered by PHARMAC’s Board (or its delegate) prior to making a decision on this proposal.
Your feedback may be shared
Feedback we receive is subject to the Official Information Act 1982 (OIA). Please be aware that we may need to share your feedback, including your identity, in response to an OIA request. This applies to anyone providing feedback, whether they are providing feedback themselves or for an organisation, in a personal or professional capacity.
We can only keep feedback confidential as allowed under the OIA and other related laws. If you want any part of your feedback treated as confidential, you need to tell us. Please let us know if you want to keep part of your feedback confidential, and why. Is it commercially sensitive, confidential or proprietary, or personal information? Clearly state this and tell us which parts of your feedback you want to keep confidential for these reasons. We will consider your request under our OIA requirements.